[PDF] Top 20 CD200 is a new prognostic factor in multiple myeloma.
Has 10000 "CD200 is a new prognostic factor in multiple myeloma." found on our website. Below are the top 20 most common "CD200 is a new prognostic factor in multiple myeloma.".
CD200 is a new prognostic factor in multiple myeloma.
... the CD200 gene in multiple myeloma cells (MMC) of 112 patients with newly-diagnosed multiple myeloma ...The CD200 gene was either absent or present (Affymetrix call) ... Voir le document complet
13
Heparanase influences expression and shedding of syndecan-1, and its expression by the bone marrow environment is a bad prognostic factor in multiple myeloma.
... with myeloma, after written informed consent was given. Biopsies were fixed in Bouin’s, decalcified and routinely processed for paraffin ...deparaffined in xylene and rehydrated through graded ... Voir le document complet
43
MYEOV is a prognostic factor in multiple myeloma.
... overexpression in multiple myeloma revealed by fluorescence in situ hybridization and quantitative analysis of mRNA ...MYEOV, a gene at 11q13, is coamplified with CCND1, but ... Voir le document complet
35
The role of IGF-1 as a major growth factor for myeloma cell lines and the prognostic relevance of the expression of its receptor.: IGF-1 is the major growth factor on myeloma
... Introduction Multiple myeloma (MM) is a clonal plasma-cell ...disorder. Multiple myeloma cells (MMC) from almost all patients harbor chromosomal abnormalities by FISH 1,2 and ... Voir le document complet
42
Programmed death–ligand 1 and vimentin: A tandem marker as prognostic factor in NSCLC
... EMT is characterized by diminished epithelial characteristics and enhanced mesenchymal ...parameters in a variety of cancers including NSCLC [ 9 ]. Vimentin, a canonical marker and actor of ... Voir le document complet
14
Input of DNA microarrays to identify novel mechanisms in multiple myeloma biology and therapeutic applications.: DNA microarrays in multiple myeloma
... (34). A quarter of those genes were also identified by Zhan et al (35), like MYC and cyclin D1, using purified bone marrow plasma cells from healthy individuals as a normal counterpart of myeloma ... Voir le document complet
24
The anti-tumoral effect of lenalidomide is increased in vivo by hypoxia-inducible factor (HIF)-1α inhibition in myeloma cells.
... report a sig- nificant reduction in bone marrow MVD in MM patients treated with new drugs, including ...suppression in MM cells significantly increases the anti-MM in vivo effect ... Voir le document complet
5
The Bcl-2 family member Bfl-1/A1 is strongly repressed in normal and malignant plasma cells but is a potent anti-apoptotic factor for myeloma cells.
... Manz, R.A., Arce, S., Cassese, G., Hauser, A.E., Hiepe, F. & Radbruch, A. (2002) Humoral immunity and long-lived plasma cells. Curr Opin Immunol, 14, 517- 521. Medina, F., Segundo, C., Campos-Caro, A., ... Voir le document complet
34
Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network.
... Diarrhea is a common side effect of novel drugs, and more frequently observed during exposure with bortezomib, lenalidomide, and ...Diarrhea in general was rare in patients exposed to ... Voir le document complet
19
Cellular immunotherapy in multiple myeloma : lessons from preclinical models
... with a strong inhibitory function, potentially inhibiting anti-myeloma immune control after transplantation [62] ...are a heterogeneous population of immature myeloid cells with immune suppressive ... Voir le document complet
13
Treatment of Multiple Myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group
... Center, New York, NY; Philippe Moreau, University Hospital, Nantes, France; Amara Nouel, Hospital Rutz y Paez, Bolivar, Venezuela; Robert Orlowski, MD Anderson Cancer Center, Houston, TX; Antonio Palumbo, ... Voir le document complet
9
Cancer/Testis genes in multiple myeloma: expression patterns and prognosis value determined by microarray analysis.: Expression of cancer-testis genes in multiple myeloma
... Introduction Multiple myeloma (MM) is a B cell neoplasia characterized by the accumulation of malignant plasma cells in the bone ...achieved in about 25-50% of newly-diagnosed ... Voir le document complet
34
Aboriginal status is a prognostic factor for mortality among antiretroviral naïve HIV-positive individuals first initiating HAART
... interest in this study: (1) time to HIV plasma viral load suppression as measured from the time of starting HAART to the first of two consecutive plasma HIV viral loads of < 500 copies/ ml; (2) CD4 cell ... Voir le document complet
9
Identification of a new HLA-A2-restricted T-cell epitope within HM1.24 as immunotherapy target for multiple myeloma.
... h in anti-IFN-γ-antibody [Mabtech AB, Nacka, Sweden] coated nitrocellulose-plates [Millipore, Eschborn, ...with a computer controlled microscope [Zeiss-Vision, Eching, ...used a high 4:1 ... Voir le document complet
26
DEPTOR Is an mTOR Inhibitor Frequently Overexpressed in Multiple Myeloma Cells and Required for Their Survival
... DEPTOR Is Phosphorylated in an mTOR-Dependent Fashion Because the mTOR inhibitor Torin 1 prevents the serum-induced degradation and SDS-PAGE mobility shift of DEPTOR, we reasoned that a mechanism ... Voir le document complet
15
Plasma Circulating Tumor DNA in Pancreatic Cancer Patients Is a Prognostic Marker
... collected in the Pitié Salpêtière hospital (Paris, France) including resectable, locally advanced and metastatic ...resection in patients who had curative resection, or (ii) the first cycle of chemotherapy ... Voir le document complet
31
Younger age as a bad prognostic factor in patients with carcinoma of the cervix.
... The influence of treatment time on outcome for squamous cell cancer of the uterine cervix treated with radiation: A patterns-of-care study.. Overall treatment time in[r] ... Voir le document complet
5
Gene expression profiling and real-time PCR analyses identify novel potential cancer-testis antigens in multiple myeloma.: Novel cancer-testis genes in multiple myeloma
... Materials and methods Patients and cell samples Primary MM cells (MMC) were purified from 64 consecutive patients with newly-diagnosed MM (median age, 59 years). According to Durie-Salmon classification, 11 patients were ... Voir le document complet
16
Bone marrow mesenchymal stem cells are abnormal in multiple myeloma.
... hypothesis in multiple myeloma (MM), we studied bone marrow mesenchymal stem cells (BMMSCs), the only long-lived cells of the bone marrow microenvironment, by gene expression with Affymetrix arrays ... Voir le document complet
36
Expressed fusion gene landscape and its impact in multiple myeloma
... observed in at least two patients and up to 115 ...either a non-stochastic generation mechanism, or the existence of a selective pressure for fusions in the tumor ...clones. In total, ... Voir le document complet
11
Sujets connexes